Prediction of conversion from mild cognitive impairment to Alzheimer's disease and simultaneous feature selection and

Qi Zhang1, Ron Coury2, Wenlong Tang3

  • 1Department of Mathematics and Statistics, University of New Hampshire, Durham, NH, 03824, USA. qi.zhang2@unh.edu.

PubMed
Abstract

Insights

Predicting Alzheimer's disease (AD) progression from Mild Cognitive Impairment (MCI) is crucial. Tree-guided lasso regularization effectively identified key features for accurate AD risk prediction using real-world data.

Area of Science:

  • Neurology
  • Data Science
  • Biostatistics

Background:

  • Mild Cognitive Impairment (MCI) patient heterogeneity necessitates early prediction of Alzheimer's disease (AD) conversion.
  • Routinely collected real-world data, including electronic health records and administrative claims, are vital for risk prediction.

Purpose of the Study:

  • To develop and validate a method for predicting the risk of conversion from MCI to AD.
  • To identify robust and interpretable feature groups predictive of AD progression using real-world data.

Main Methods:

  • Utilized MarketScan Multi-State Medicaid data to form an MCI patient cohort.
  • Employed logistic regression with tree-guided lasso regularization (TGL) for feature selection and AD risk prediction.
  • Applied a subsampling technique to extract robust predictive feature groups and trained various predictive models.

Main Results:

  • The TGL workflow successfully identified feature groups that were robust, interpretable, and aligned with existing literature.
  • Predictive models utilizing TGL-selected features achieved higher accuracy compared to models using all features or other selection methods.

Conclusions:

  • The identified feature groups offer valuable insights into MCI to AD progression.
  • This approach has the potential to enhance clinical practice and patient recruitment for AD trials.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
113